Статус неизвестен
Россия
ESR-17-13290 · N.N. Blokhin National Medical Research Center of Oncology
Multicenter Non-interventional Study of Osimertinib Administration in Patients With NSCLC Progression Occurred During or After Therapy With EGFR Tyrosine Kinase Inhibitors, With Confirmed Т790М Positive Mutation in EGFR Gene